FDA Approvals for Liver and Stomach Cancer Extend the Reach of Immunotherapy

Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which immunotherapeutics known as checkpoint inhibitors are a treatment option when it expanded the approved uses of nivolumab (Opdivo) and pembrolizumab (Keytruda) to include certain patients with liver cancer and stomach cancer, respectively.

Read More

One More Reason to Stay Trim: Reduce Your Liver Cancer Risk

Liver cancer rates have been on the rise in the United States and have tripled in the last four decades. A study published in 2014 in the AACR’s journal Cancer Research projected that pancreatic cancer and liver cancer will surpass breast, prostate, and colorectal cancers to become the second and third leading causes of cancer death, following lung cancer.

Read More